NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
6/8 — Strong
ARISTADA INITIO KIT (aripiprazole lauroxil) by Alkermes is aripiprazole. Approved for schizophrenia. First approved in 2018.
Drug data last refreshed 19h ago
Mechanism of Action
aripiprazole. Following intramuscular injection, aripiprazole lauroxil is likely converted by enzyme-mediated hydrolysis to N -hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. The mechanism of action of aripiprazole in schizophrenia is unclear. However, efficacy could be…
Indications (1)
Clinical Trials (7)
C-Cog in Early Course Schizophrenia Study
Started Jan 2024
1 enrolled
Schizophrenia
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Started Dec 2019
15 enrolled
SchizophreniaSchizoaffective Disorder, Depressive TypeSchizophreniform Disorder
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Started Nov 2017
200 enrolled
Schizophrenia
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Started Dec 2015
47 enrolled
SchizophreniaSchizoaffective Disorder
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
Started Dec 2015
51 enrolled
Schizophrenia
Worked on ARISTADA INITIO KIT at Alkermes? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.